Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-9: durvalumab with oleclumab or monalizumab after concurrent chemoradiotherapy in unresectable stage III NSCLC
CTR20221537Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, oleclumab, monalizumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2022; status: active.
02
Drugs
durvalumaboleclumabmonalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221537.